LOOK TO
GAVRETO is the only once-daily therapy designed to selectively target RET1
LOOK TO
PUSH RET
BACK
GAVRETO is the only once-daily therapy
designed to selectively target RET1
RIGEL is committed to providing support to ensure that there is no delay in therapy for new or existing patients.
RIGEL ONECARE® has a staff of nurses fully trained to support patients prescribed GAVRETO, whether their GAVRETO is fulfilled through integrated, in-office dispensing or specialty pharmacies.
Enroll your current and new patients at RigelONECARE.com for ongoing support
Services provided by
RIGEL ONECARE include:
Transitioning
existing patients
into Rigel network
pharmacies
Benefits
investigation,
prior authorization,
and appeals
resources
Copay
assistance*
Temporary and
long-term free
drug supply*
Adherence
support and
product-education
phone calls
*All Rigel programs are subject to eligibility requirements. Restrictions may apply.
FAQs
Below are some frequently asked questions about the acquisition.
There should be no delays or interruptions in coverage or access to GAVRETO.
Inform your patients that they may need to receive GAVRETO through a new pharmacy. Patients may receive a call from their new pharmacy to verify or alter information to ensure access to GAVRETO.
If you have concerns or questions related to accessing GAVRETO, please contact RIGEL ONECARE.
You can request refills or order new prescriptions through the RIGEL ONECARE Enrollment Form
Visit RIGEL ONECARE for information related to product distribution.
Call 1-800-983-13291-800-983-1329 or email us at producthelp@rigel.com.
Please report any medical inquiries, product complaints, or adverse events to Rigel Medical Communications Center at 1-800-983-13291-800-983-1329 or producthelp@rigel.com. You may also report adverse events associated with taking our prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088)1-800-FDA-1088 (1-800-332-1088).
Reference
1. GAVRETO® [Package insert], South San Francisco, CA: Rigel Pharmaceuticals, Inc.